Anaconda Biomed is a Barcelona based medical device start-up co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies.

Stroke is the first cause of permanent disability in the world. The burden for the national health systems can be quantified in billions of dollars.

As numerous research has proven over the last few years, the best treatment in case of an Acute Ischemic Stroke is to perform a mechanical thrombectomy. Dr. Ribo’s research published on April 2015 on the New England Journal of Medicine* prove to be the stroke that broke the medical community camel’s back.

*Additional Source
New England Journal of Medicine
Source Reference: Furlan AJ "Endovascular therapy for stroke -- it's about time" N Engl J Med 2015; DOI: 10.1056/NEJMe1503217.

Learn more Close


Dr. Marc Ribó

Interventional Neurologist

Neurology degree at Hospital Vall d’Hebron, Barcelona 2003. Stroke Fellowship at University of Texas- Houston (2004-5). PhD in Medicine at Universtitat Autònoma de Barcelona (2004). He developed his professional activity in the field of cerebrovascular diseases with special interest in the acute phase of ischemic stroke and in particular in promoting reperfusion treatments either systemic or endovascular. His research activity in the acute phase of stroke includes a large experience in the design of clinical trials, research projects with public or private funding, direction of several doctoral thesis, and signing more than 150 peer reviewed publications. His research activity includes also the development of telemedicine solutions to increase and accelerate the access to best therapies to all acute stroke patients.

Dr. Ofir Arad

Co-founder & CEO

Degree in Chemical Sciences at Institut Químic de Sarrià, Barcelona 2000. PhD in Organic Chemistry, Barcelona 2012. Dr. Arad has 15 years of experience in the biomedical field. After a period developing pharmaceutical compounds and photosensitizers for Cancer Photodynamic Therapy, he has developed materials for the medical devices industry: biopolymers and their formulations for controlled drug release applications, lubricious coatings and radiopaque materials for endovascular catheters, chemical enhancement of biomaterials for aortic percutaneous valves and advanced adhesives for medical applications. In the last 7 years he has been leading several projects of medical devices (mainly drug eluting stents and thrombus aspiration catheters) for interventional cardiology applications. He has also been working as chemical research director for a consolidated medical device company.

Uri Fligil


In the beginning of his career Uri launched a start-up in the cardiovascular field in his homeland: Israel. After that, Uri worked at Medtronic Sarl (Swiss HQ). There, he held several sales and marketing leadership roles in Europe and Latin America. His roles included product management for the coronary stent marketing group, which achieved over $200 million in annual sales, and Cardiovascular business unit manager in Eastern Europe and Central Asia holding P&L generating about $20 million annual sales. Uri coursed Business Management in Israel (The College of Management) and an MBA at IESE Business School in Barcelona Spain. He has worked intensively in Israel, Switzerland, USA, Holland and Spain, having acquired great experience in the medical sector.

Dr. Iñaki Galve

R&D director

Chemistry degree at Institut Químic de Sarrià (IQS), Barcelona 2003. Master Degree in Organic Chemistry and Biochemistry at IQS, Barcelona 2008. PhD in Drug Discovery (Organic Chemistry) at IQS, Barcelona 2013. He has successfully worked in drug discovery, biopolymers and medical devices development both in research and management roles. His main fields of working include cancer, immunological and neurodegenerative disorders and cardiovascular diseases. As technical staff, he has been involved from early stages of product conception to late regulatory and industrialization stages with excellent results. His recent achievements have been in the field of cardiovascular medical devices, mainly drug eluting stents.

Alain Garcinuño

Consultant, Business Angel

MSc. in Finance by HEC Paris in 2004, MSc. in Engineering by UPC Barcelona in 2002 Alain worked at several financial institutions in Paris, London and Geneva, including Citigroup and Credit Suisse covering several asset classes, from fixed income derivatives, to private equity. In his role, Alain developed relationships with banks, family offices, asset managers and insurance companies. In 2012, Alain started his own consultancy firm and became an active serial entrepreneur leveraging on an extensive network of business angels. He is currently involved in the space of renewable energy, medtech and innovative solutions for real estate. Alain speaks fluently several languages, including English, French and Spanish

Anaconda Biomed

Anaconda Biomed is a Barcelona based medical device start-up co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies.